TH-012(Bangentai Biomedical)

N/A

Report date: 2022/12/31 20:52:40

Base Information

Drug NameTH-012(Bangentai Biomedical)
Drug Alias NameTH-012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A